|
1
|
National Comprehensive Cancer Network
(NCCN), . Non-Small Cell Lung Cancer (NCCN Guidelines®).
NCCN; Plymouth Meeting, PA: 2024
|
|
2
|
Patel RB, Hernandez R, Carlson P,
Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I,
Aluicio-Sarduy E, et al: Low-dose targeted radionuclide therapy
renders immunologically cold tumors responsive to immune checkpoint
blockade. Sci Transl Med. 13:eabb36312021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et
al: PACIFIC investigators. Overall survival with durvalumab after
chemoradiotherapy in stage III NSCLC. N Engl J Med. 379:2342–2350.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stucci S, Palmirotta R, Passarelli A,
Silvestris E, Argentiero A, Lanotte L, Acquafredda S, Todisco A and
Silvestris F: Immune-related adverse events during anticancer
immunotherapy: Pathogenesis and management. Oncol Lett.
14:5671–5680. 2017.PubMed/NCBI
|
|
5
|
Wang CL, Ho AS and Cheng CC, Sie ZL, Peng
CL, Chang J and Cheng CC: Radiotherapy enhances
CXCR3highCD8+ T cell activation through
inducing IFNγ-mediated CXCL10 and ICAM-1 expression in lung cancer
cells. Cancer Immunol Immunother. 72:1865–1880. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
U.S. Department of Health and Human
Services, . Common Terminology Criteria for Adverse Events Version
5.0 (CTCAE v5.0).
|
|
7
|
Chang W: R Graphics Cookbook. O'Reilly
Media; 2013
|
|
8
|
Goldstraw P, Crowley J, Chansky K,
Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P,
Mitchell A, Bolejack V, et al: The IASLC lung cancer staging
project: Proposals for the revision of the TNM stage groupings in
the forthcoming (Eighth) edition of the TNM classification for lung
cancer. J Thorac Oncol. 10:1260–1271. 2015.
|
|
9
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shaverdian N, Lisberg AE, Bomazyan K,
Veruttipong D, Goldman JW, Formenti SC, Garon EB and Lee P:
Previous radiotherapy and the clinical activity and toxicity of
pembrolizumab in the treatment of non-small cell lung cancer: A
secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol.
8:895–903. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ross GM: Induction of cell death by
radiotherapy. Endocr Relat Cancer. 6:41–44. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vinod SK and Hau E: Radiotherapy treatment
for lung cancer: Current status and future directions. Respimlogy.
25 (Suppl 2):S61–S71. 2020. View Article : Google Scholar
|
|
13
|
Uribe-Herranz M, Rafail S, Beghi S,
Gil-de-Gómez L, Verginadis I, Bittinger K, Pustylnikov S, Pierini
S, Perales-Linares R, Blair IA, et al: Gut microbiota modulate
dendritic cell antigen presentation and radiotherapy-induced
antitumor immune response. J Clin Invest. 130:466–479. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu L, Bai H, Wang C, Seery S, Wang Z,
Duan J, Li S, Xue P, Wang G, Sun Y, et al: Efficacy and safety of
first-line lmmunotherapy combinations for advanced NSCLC: A
systematic review and network meta-analysis. J Thorac Oncol.
16:1099–1117. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hen'era FG, Irving M, Kandalaft LE and
Coukos G: Rational combinations of immunotherapy with radiotherapy
inovarian cancer. Lancet Oncol. 20:e417–e433. 2019. View Article : Google Scholar
|
|
16
|
Nishino M, Giobbie-Hurder A, Hatabu H,
Ramaiya NH and Hodi F: Incidence of programmed cell death 1
inhibitor-related pneumonitis in patients with advanced cancer: A
systematic review and meta-analysis. JAMA Oncol. 2:1607–1616. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jabbour SK, Berman AT, Decker RH, Lin Y,
Feigenberg SJ, Gettinger SN, Aggarwal C, Langer CJ, Simone CB,
Bradley JD, et al: Prospective phase I multi-institutional trial of
PD-1 blockade with pembrolizumab during concurrent chemoradiation
for locally advanced, unresectable non-small cell lung cancer. J
Clin Oncol. 37:85112019. View Article : Google Scholar
|
|
18
|
Lu X, Wang J, Zhang T, Zhou Z, Deng L,
Wang X, Wang W, Liu W, Tang W, Wang Z, et al: Comprehensive
pneumonitis profile of thoracic radiotherapy followed by immune
checkpoint inhibitor and risk factors for radiation recall
pneumonitis in lung cancer. Front Immunol. 13:9187872022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang HY, Gong HY and Song QB: Influencing
factors of pneumonitis in the period of thoracic radiotherapy
combined with immunotherapy. J Int Oncol. 50:102–106. 2023.(In
Chinese).
|
|
20
|
Chen K and Sun B: Incidence and risk of
PD-1/PD-L1 inhibitor-associated pneumonia in advance cancer
patients: A meta-analysis. Zhongguo Fei Ai Za Zhi. 23:927–940.
2020.(In Chinese). PubMed/NCBI
|
|
21
|
Delaunay M, Cadranel J, Lusque A, Meyer N,
Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N,
Guisier F, et al: Immune checkpoint inhibitors associated with
interstitial lung disease in cancer patients. Eur Respir J.
50:17000502017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu XT, Wang JY, Zhang T, Zhou Z, Deng L,
Wang X, Wang W, Liu W, Tang W, Wang Z, et al: Comprehensive
Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune
Checkpoint Inhibitor and Risk Factors for Radiation Recall
Pneumonitis in Lung Cancer. Front Immunol. 13:9187872022.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Saito G, Oya Y, Taniguchi Y, Kawachi H,
Daichi F, Matsumoto H, Iwasawa S, Suzuki H, Niitsu T, Miyauchi E,
et al: Real-world survey of pneumonitis/radiation pneumonitis among
patients with locally advanced non-small cell lung cancer treated
with chemoradiotherapy after durvalumab approval: A multicenter
retrospective cohort study (HOPE-005/CRIMSON). J Clin Oncol.
38:90392020. View Article : Google Scholar
|
|
24
|
Chen Y, Liu X, Huang Z, Zhao K, Wang Y,
Ren F, Yu J and Meng X: Safety of thoracic radiotherapy after
PD-(L)1 inhibitor treatment in patients with lung cancer. Cancer
Med. 10:8518–8529. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin SH, Lin Y, Yao L, Kalihor N, Carter
BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, et
al: Phase II Trial of Concurrent Atezolizumab With Chemoradiation
for Unresectable NSCLC. J Thorac Oncol. 15:248–257. 2020.
View Article : Google Scholar : PubMed/NCBI
|
